MedPath

A Study to Evaluate the Food Effect on the Pharmacokinetics of NVP-1203

Phase 1
Completed
Conditions
Healthy
Interventions
Registration Number
NCT02289404
Lead Sponsor
NVP Healthcare
Brief Summary

The purpose of this study is to evaluate food effect on the pharmacokinetics of NVP-1203

Detailed Description

This study is designed as randomized, open-label, crossover assignment for evaluate the food effect on the pharmacokinetics of NVP-1203 in healthy adult subjects

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
39
Inclusion Criteria
  • healthy adult subjects who signed informed consent
Exclusion Criteria
  • Subjects has a history of allergy reaction of study drug ingredient
  • Subjects participated in another clinical trial within 3 months prior to administration of the study drug
  • Inadequate subject for the clinical trial by the investigator's decision

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
NVP-1203(fed then fasting)NVP-1203Subjects will receive a oral dose of NVP-1203 under fed conditions in period 1, then subjects will receive a oral dose of NVP-1203 under fasting conditions in period 2
NVP-1203(fasting then fed)NVP-1203Subjects will receive a oral dose of NVP-1203 under fasting conditions in period 1, then subjects will receive a oral dose of NVP-1203 under fed conditions in period 2
Primary Outcome Measures
NameTimeMethod
Pharmacokinetics : Cmax0-24 hours

Maximum plasma concentration

Pharmacokinetics : AUCt0-24 hours

Area under the concentration-time curve

Secondary Outcome Measures
NameTimeMethod
Pharmacokinetics : AUCinf0-24 hours

AUC extrapolated to infinity

Pharmacokinetics : t1/20-24 hours

Terminal elimination half-life

Pharmacokinetics : Tmax0-24 hours

Time to reach the Cmax

Trial Locations

Locations (1)

Kyungpook National University Hospital

🇰🇷

Daegu, Dongdeok-ro, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath